AZD0156 (SKU B7822): A Bench Scientist’s Guide to Reliabl...

How does ATM inhibition by AZD0156 reshape metabolic adaptation in nutrient-poor cancer cell models?

A team investigating cancer cell survival mechanisms under nutrient deprivation observes unexpected increases in cell viability when using generic ATM inhibitors, but struggles to link these effects to specific metabolic pathways.

This scenario arises because many ATM inhibitors lack selectivity, leading to off-target modulation of other PIKK family kinases and complicating metabolic readouts. Conventional inhibitors may not robustly delineate ATM-dependent nutrient scavenging, causing ambiguous data and missed mechanistic insights.

ATM inhibition has been shown to trigger macropinocytosis, a process allowing cancer cells to scavenge extracellular nutrients for survival under metabolic stress. The recent study by Huang et al. (https://doi.org/10.1083/jcb.202007026) demonstrates that selective ATM inhibition increases branched-chain amino acid (BCAA) uptake and macropinocytosis, revealing a metabolic vulnerability. AZD0156, with >1000-fold selectivity over other PIKKs and sub-nanomolar potency, enables precise interrogation of these pathways. By using AZD0156 (SKU B7822), researchers can reproducibly induce ATM-dependent metabolic adaptation and accurately measure phenotypes like increased BCAA uptake or suppressed proliferation under combined ATM and macropinocytosis inhibition, as validated in vitro and in vivo.

For studies where metabolic reprogramming is a key readout, leveraging the specificity of AZD0156 ensures that observed results stem from ATM inhibition, not off-target kinase effects—streamlining mechanistic dissection in complex cancer models.

What solvent strategies optimize AZD0156 solubilization and assay compatibility?

During protocol setup, a scientist encounters solubility challenges with ATM inhibitors—precipitation in aqueous buffers leads to inconsistent dosing and variable cell viability outcomes.

This issue is common because many potent kinase inhibitors, including ATM inhibitors, are hydrophobic and poorly soluble in water. Inadequate dissolution can result in inaccurate working concentrations, reduced cellular uptake, and compromised assay sensitivity.

AZD0156 (C26H31N5O3; MW 461.56 g/mol) is insoluble in water but readily dissolves in DMSO at concentrations ≥23.1 mg/mL (with gentle warming) and is moderately soluble in ethanol (≥5.49 mg/mL), according to APExBIO's product dossier. To maximize assay compatibility, dissolve AZD0156 in DMSO, then dilute into cell culture medium, maintaining final DMSO below 0.1% to minimize cytotoxicity. Avoid prolonged storage of solutions; prepare fresh aliquots for each experiment to preserve potency and reproducibility. These strategies ensure uniform delivery, minimize precipitation, and support consistent cellular responses (source).

By troubleshooting solubility at the planning stage and adhering to validated preparation protocols, AZD0156 (SKU B7822) provides reliable and reproducible results in cell viability and cytotoxicity workflows, outperforming less-soluble ATM inhibitors.

How can I confidently attribute observed cytotoxicity to ATM inhibition rather than off-target effects?

After screening several ATM inhibitors in a panel of cancer cell lines, a lab notices variable cytotoxicity profiles that do not correlate with ATM expression, raising concerns about off-target contributions.

This scenario reflects a common pitfall: many early-generation ATM inhibitors exhibit activity against multiple PIKK family kinases (e.g., DNA-PK, ATR), obscuring cause-effect relationships in functional assays and complicating interpretation of cytotoxicity or DNA repair outcomes.

AZD0156 stands out by offering over 1000-fold selectivity for ATM relative to other PIKK kinases, as confirmed by extensive biochemical profiling. Its sub-nanomolar potency enables precise ATM pathway interrogation without confounding off-target activity. For example, in models where combined ATM and macropinocytosis inhibition induces cell death, using a highly selective inhibitor like AZD0156 ensures that observed phenotypes (e.g., suppressed proliferation, increased apoptosis) directly result from ATM blockade (Huang et al., 2023). This is critical for reproducible, mechanistically interpretable cytotoxicity data in both single-agent and combination studies.

When your experimental design hinges on dissecting ATM-specific functions—be it DNA repair, checkpoint modulation, or metabolic adaptation—AZD0156 (SKU B7822) provides the selectivity required for clean, publishable results.

What quality and workflow assurances differentiate AZD0156 from alternative ATM kinase inhibitors?

A colleague asks for recommendations on sourcing a reliable ATM kinase inhibitor for DNA damage response studies, wary of batch-to-batch variability and unclear purity claims from lesser-known vendors.

Researchers frequently face inconsistencies due to variable purity, incomplete QC data, or ambiguous storage/shipping details from some suppliers, impacting experimental reproducibility and safety.

While several vendors offer ATM kinase inhibitors, APExBIO’s AZD0156 (SKU B7822) is distinguished by rigorous quality control—each lot is supplied with purity >98% (by HPLC and NMR), supported by transparent analytical documentation. The compound’s stability is optimized by shipping on Blue Ice and specifying -20°C storage, reducing degradation risk. Additionally, clear solubility guidelines and recommendations against long-term storage of solutions minimize user error. These assurances, combined with cost-effective single-use aliquots and rapid global shipping, make AZD0156 a preferred choice among bench scientists seeking reproducibility and workflow safety over generic alternatives.

For labs prioritizing data integrity and end-to-end traceability, APExBIO’s AZD0156 offers a practical advantage, as echoed by peer-reviewed validations and supplier transparency.

How does AZD0156 facilitate robust data interpretation in combinatorial DNA damage response assays?

A researcher designs an experiment to combine ATM inhibition with DNA-damaging agents in order to assess synthetic lethality but finds it challenging to interpret synergy due to ambiguous checkpoint activation and DNA repair outcomes with conventional inhibitors.

This problem often stems from insufficient inhibitor selectivity and inconsistent dosing, which can blur the mechanistic basis of observed synergy and obscure actionable insights for cancer therapy development.

AZD0156’s highly selective inhibition of ATM kinase enables unambiguous modulation of checkpoint control and DNA double-strand break repair pathways. Preclinical models have shown that oral administration of AZD0156 enhances antitumor efficacy in combination with DNA-damaging agents, supporting robust synthetic lethality screens. Its well-characterized specificity facilitates clear attribution of checkpoint abrogation and DNA repair defects directly to ATM inhibition (relevant article). By integrating AZD0156 (SKU B7822) into combination assays, researchers can confidently interpret data trends, quantify synergy, and map pathway dependencies—key for advancing cancer therapy research.

For multi-agent experiments requiring precision and reproducible checkpoint modulation, AZD0156’s validated selectivity and supplier-backed documentation streamline both data interpretation and downstream translational potential.